[ad_1]
Seattle, March 20, 2024–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today Announced that the company will participate in HC Wainwright 2ND Annual Autoimmune and Inflammatory Diseases Virtual Conference.
-
Thursday, March 28thAlpine Chief Commercial Officer Dr. Remy Durand will participate in a fireside chat at 3:00 pm ET/12:00 pm PT the same day as the company’s investor conference.
A live webcast of the Fireside Chat will be available on the Investor Relations section of the Company’s website: https://ir.alpineimmunesciences.com/events, and a replay will be available on the Company’s website for 90 days following the event.
About Alpine Immunology
Alpine Immune Sciences is committed to leading the new wave of immunotherapy. With world-class R&D capabilities, a highly effective scientific platform and a proven management team, Alpine is committed to creating first-in-class or best-in-class multifunctional immunotherapies through unique protein engineering technologies to improve patients’ lives. Alpine has established strategic collaborations with leading global biopharmaceutical companies and has multiple clinical and preclinical drug candidates in development. For more information, please visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci X and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320830092/en/
contact method
Media and Investor Relations:
ir@alpineimmunesciences.com
media@alpineimmunesciences.com
[ad_2]
Source link